Business
Marketing approval of drugs in the United States requires the submission of a new drug application, or NDA, to the FDA and we are not permitted to market any drug candidate in the United States until we obtain approval of the NDA.
Fulcrum Therapeutics, Inc.: Revenue declined 100% to $0 from $80M. Net loss widened to $74.88M from $9.725M. Free cash flow outflow widened to $60.38M from $2.496M. Net margin was unavailable and was not inferred. Fulcrum Therapeutics, Inc.'s annual comparison also shows capital spending grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 100% to $0 from $80MWatch
- Profitability — Net loss widened to $74.88M from $9.725MWatch
- Cash flow — Free cash flow outflow widened to $60.38M from $2.496MWatch
- Margins — Net margin was unavailable and was not inferredNote
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 5 salesWatch
Where the revenue comes from
Fiscal 2024, as Fulcrum Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Sanofi Agreement$80.0M
Leadership changes
From Fulcrum Therapeutics, Inc.'s own filings, the day they're filed.
- Greg Tourangeau · President · departureeff. 2026-06-10
- Rachel King · director · departureeff. 2024-11-12
Latest filings
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-06-25
- 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Fulcrum Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.